Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.88 Billion CNY | 73.06% |
| 2022 | 1.66 Billion CNY | -4.45% |
| 2021 | 1.74 Billion CNY | -11.39% |
| 2020 | 1.97 Billion CNY | 515.2% |
| 2019 | 320.26 Million CNY | -29.59% |
| 2018 | 454.88 Million CNY | 208.12% |
| 2017 | 147.63 Million CNY | 7.6% |
| 2016 | 137.2 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.1 Billion CNY | 7.53% |
| 2024 Q2 | 3.09 Billion CNY | -0.16% |
| 2024 Q3 | 2.96 Billion CNY | -4.28% |
| 2023 Q4 | 2.88 Billion CNY | 0.98% |
| 2023 Q2 | 2.87 Billion CNY | 72.43% |
| 2023 FY | 2.88 Billion CNY | 73.06% |
| 2023 Q1 | 1.66 Billion CNY | -0.2% |
| 2023 Q3 | 2.85 Billion CNY | -0.41% |
| 2022 Q3 | 1.63 Billion CNY | 0.47% |
| 2022 Q4 | 1.66 Billion CNY | 2.16% |
| 2022 Q2 | 1.62 Billion CNY | -3.79% |
| 2022 Q1 | 1.68 Billion CNY | -3.24% |
| 2022 FY | 1.66 Billion CNY | -4.45% |
| 2021 FY | 1.74 Billion CNY | -11.39% |
| 2021 Q1 | 1.91 Billion CNY | -2.77% |
| 2021 Q4 | 1.74 Billion CNY | -5.71% |
| 2021 Q3 | 1.85 Billion CNY | -3.83% |
| 2021 Q2 | 1.92 Billion CNY | 0.51% |
| 2020 Q1 | 2.11 Billion CNY | 559.82% |
| 2020 FY | 1.97 Billion CNY | 515.2% |
| 2020 Q3 | 2 Billion CNY | -1.81% |
| 2020 Q2 | 2.03 Billion CNY | -3.5% |
| 2020 Q4 | 1.97 Billion CNY | -1.6% |
| 2019 Q1 | 379.92 Million CNY | -16.48% |
| 2019 Q2 | 376.57 Million CNY | -0.88% |
| 2019 Q3 | 296.73 Million CNY | -21.2% |
| 2019 Q4 | 320.26 Million CNY | 7.93% |
| 2019 FY | 320.26 Million CNY | -29.59% |
| 2018 FY | 454.88 Million CNY | 208.12% |
| 2018 Q4 | 454.88 Million CNY | 0.0% |
| 2017 FY | 147.63 Million CNY | 7.6% |
| 2016 FY | 137.2 Million CNY | 0.0% |